oct 2015 webinar: dr. lieu, precision medicine
TRANSCRIPT
Precision Medicine and ImmunotherapyResearch Advocacy Training and Support Program
Our webinar will begin shortly.
WELCOME!
• Speaker(s): Dr. Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program
• Archived Webinars: FightColorectalCancer.org/Webinars
• AFTER THE WEBINAR: Expect an email with links to the recording.
• Ask a question in the panel on the RIGHT SIDE of your screen
• Follow along via Twitter – use the hashtag #CRCWebinar
Today’s Webinar:
What is a RESEARCH ADVOCATE? A research advocate brings a patient viewpoint to the research process and communicates a collective patient perspective
Fight CRC’s Research Advocacy Training and Support (RATS) Program: • Goal is to improve the ability of research
advocates to effectively participate in the research process.
• In person meetings, online trainings, and webinars.
• Continued education and ongoing training and support
Brought to you by RATS:
Resources:
Disclaimer:
The information and services provided by Fight Colorectal Cancer are for general informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnoses or treatment.
If you are ill, or suspect that you are ill, see a doctor immediately. In an emergency, call 911 or go to the nearest emergency room.
Fight Colorectal Cancer never recommends or endorses any specific physicians, products or treatments for any condition.
Speaker: Chris Lieu, M.D.
Dr. Lieu is one of our hosts for the research advocacy training at the University of Colorado. Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2011.
He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010.
Precision Medicine and ImmunotherapyResearch Advocacy Training and
Support
Christopher Lieu, MDUniversity of Colorado
Gastrointestinal Malignancies ProgramOctober 22, 2015
Christopher Lieu, MDUniversity of ColoradoGastrointestinal Malignancies Program
Christopher Lieu, MDUniversity of ColoradoGastrointestinal Malignancies Program
Agenda• Know Your Biomarker
• Science Behind Biomarkers
• Immunotherapy
• Questions
The Science Behind Biomarkers
Show me the Data!
RAS Mutations Predict (Lack of) Benefit to EGFR Therapy
Refractory CRC RCetuximab alone
Best supportive care
Karapetis et al. NEJM 2008, 359 (17): 1757
BRAF Mutant Colon Cancer: Atypical Location of Metastases and Poor Survival
Tran, Kopetz, et al, Cancer ‘11
0%
50%
100%
150%
200%
250% BRAF wild type
P<0.05
P<0.05
P<0.05P<0.05
Incr
ease
d in
cide
nce
com
pare
d to
BR
AF
wild
type
Hazard Ratio of 10.6 for OSLess than 1 year OS
BRAF inhibition in Melanoma
BRAF Inhibition in Melanoma
Wagle et al. J Clin Oncol. 2011.
Immunotherapy
The Importance of the PD-1/PD-L1 Pathway
• Inhibiting PD-L1/PD-1 and PD-L1/B7.1 interactions can restore antitumor T-cell activity and enhance T-cell priming
• Antibodies that bind to PD-1 and PD-L1 are currently in development
• Nivolumab and pembrolizumab are currently FDA-approved
1. Akbari. Mucosal Immunol. 2010; 2. Matsumoto. Biochem Biophys Res Commun. 2008.
Mutations per tumor
Slide 12
Slide 11
Summary• Biomarker testing is becoming more common,
especially in clinical trials– Testing is usually performed by biopsy, but new
technologies are emerging (e.g. liquid biopsy)
• We are limited by what we don’t know about cancer biology– Biomarkers aren’t perfect
• Immunotherapies are emerging as effective treatment options– Currently, they do not work for all tumors
Question & Answer:
SNAP A #STRONGARMSELFIEBayer HealthCare will donate $1 for every photo posted (up to $25,000).Flex a “strong arm” & post it to Twitter or Instagram! (Use the hashtag!)